Summary: Neuroblastoma (NB) in children older than 10 years is rare. We reviewed our archives for patients with NB aged 10 to 18 years and summarized their clinicopathologic/genetic records. Of 96 patients, 4 patients were identified in this age group. Four tumors were abdominal; 1 patient had 2 tumors at diagnosis, one of which was presacral. Tumor sizes ranged from 3 to 20 cm. All tumors were high risk at clinical stages 3 and 4, with metastasis to bone marrow and other areas. Four tumors were poorly differentiated with unfavorable histology and one patient with bilateral adrenal disease had an intermixed ganglioneuroblastoma on one side. Another tumor exhibited pheochromocytoma-like morphology. MYCN amplification was present in bone marrow metastasis in one case. Complex chromosomal gains and 19p deletions were common. Exome sequencing revealed ALK variants in 2 cases and previously unreported MAGI2, RUNX1, and MLL mutations. All patients received standard chemotherapy and 2 patients received ALKtargeted trial therapy. Three patients died of disease, ranging 18 to 23 months after diagnosis. One patient has active disease and is receiving trial therapy. In conclusion, NB in children older than 10 years may exhibit unusual clinicopathologic and genetic features with large tumors, bilateral adrenal disease, rare morphologic features, complex DNA microarray findings and novel mutations. Patients often have grim prognoses despite genomic profiling-guided targeted therapy.
N euroblastoma (NB) is one of the most common malignancies in children and accounts for 15% of cancer deaths. It is most common in young children where the median age at diagnosis is 2 years. The survival of patients depends on the presence of numerous prognostic factors that include clinical presentation, tumor location, clinical stage, morphologic appearance, and biological factors. 1, 2 Age, tumor extent, and amplification of MYCN oncogene are widely accepted as major prognostic factors. The International Neuroblastoma Pathology Classification (INPC) categorizes tumors as favorable versus unfavorable histology based on Schwannian stromal development, cytodifferentiation, mitotic karyorrhectic index, and patient's age. Tumors with unfavorable histology are considered to have a poor prognosis. 3 MYCN oncogene amplification exhibits a positive correlation with high risk disease and tumor progression. 4, 5 In infants, absence of MYCN amplification usually places the patient into the low or intermediate risk groups. Other genetic events with prognostic significance include segmental chromosome changes and DNA ploidy. 6 Genomic microarray technologies identify whole chromosome changes and segmental alterations in different tumor subsets that may be used to gauge prognosis and guide treatment. 7, 8 Patients are classified into low, intermediate or high risk groups based on these prognostic factors and input from the International Neuroblastoma Staging System (INSS) and/or the International Neuroblastoma Risk Group (INRG) .
Recently, massive parallel sequencing, which has provided significant information regarding the genetic mutation burden of NB, is being utilized in planning targeted therapy. A variety of gene mutations were identified in high risk disease. In addition to MYCN, genetic alterations of ALK, PTPN11, TERT, ATRX, and NRAS are the most frequent. 9, 10 Mutations in the anaplastic lymphoma kinase (ALK) are identified in up to 15% of sporadic NB. 11 ALK inhibitors are currently being evaluated in the treatment of NB, including second generation inhibitors lorlatinib, ceritinib, and ensartinib. 12 The α-thalassemia/mental retardation X-linked (ATRX) protein is a chromatin remodeling nuclear protein and its loss contributes to alternative lengthening of telomeres through changes in gene expression, DNA replication, and histone variant deposition. 11 ATRX mutations and loss of protein expression have also been identified in high-risk NB in mutually exclusive fashion with MYCN amplifications. 13 Similarly, rearrangements of the telomerase reverse transcriptase (TERT) gene occurred in high-risk tumors in mutually exclusive manner with MYCN amplification and ATRX mutations.
The occurrence of NB in adolescents and children over 10 years of age is rare and few clinical studies are published in this age group emphasizing their bad outcome. 14, 15 This report discusses 4 such cases and presents their clinical, histologic and biologic features, including deep targeted exome sequencing, single nucleotide polymorphism (SNP) DNA microarray, and ATRX immunohistochemistry results. These methods have not been adequately published in NB in this age group.
MATERIALS AND METHODS

Patients/Subjects/Samples
Archived pathologic and clinical records of Children's Mercy Hospital (CMH) were searched for patients with the diagnosis of NB in children 10 to 18 years of age between January 2008 and November 2017. The main inclusion criterion was age older than 10 years at the time of initial diagnosis. We reviewed the histologic slides, and results of all ancillary studies including genetic work-up. We also reviewed the medical records for the clinical presentation, biochemical studies, treatment, and follow-up survival. A proper approval from the hospital research integrity board (IRB) was obtained.
Chromosomal Microarray (CMA)/Chromosomal Analysis/Fluorescence In Situ Hybridization (FISH)
Tumor DNA was extracted from fresh samples (n = 3) using the Gentra Puregene Blood Kit Plus DNA extraction kit (158489) and from formalin-fixed paraffin-embedded tissue (FFPE) (n = 1) using the Maxwell RSC FFPE DNA Kit (AS1450). Fresh tumor sample DNA was run on the Affymetrix CytoScan HD SNP+CN CMA platform and FFPE sample DNA was run on the Affymetrix OncoScan SNP+CN CMA platform, both according to the manufacturer's recommendations. The data from both platforms was analyzed using the Chromosome Analysis Suite software (Affymetrix, Santa Clara, CA).
FISH analysis was performed on bone marrow, fresh tumor, and FFPE samples using Cytocell-MYCN/AFF3 (LPS 009-A), DAKO-ALK (Y5417), and Agilen-SMARCB1 (G101010R) and NF2 (G100311G) probes. Fresh tumor (n = 3) was mechanically and enzymatically disaggregated before suspension cultures were initiated using a supplemented RPMI medium. Harvests were accomplished after 1 to 6 days. Slides were prepared and G-banded. Both FISH and chromosome results were analyzed using CytoVision analysis software (Leica, Buffalo Grove, IL).
Targeted Sequencing
FFPE tumor tissue was collected from the diagnostic specimens of 3 cases (cases 1 to 3) for deep targeted sequencing. Sequencing was performed at CLIA-certified/CAP-accredited laboratories. Adequate DNA was extracted and sequenced to identify gene variants, substitutions, short insertions/deletions, rearrangements, fusions, and amplifications. Deep sequencing included all genes known to be somatically altered in human solid tumors that have validated targets for therapy, interrogating 315 genes as well as introns of 28 genes involved in rearrangements. Sequencing was performed with Illumina HiSeq. 2500 or 4000 to a median exon coverage depth of 717×. Interpretations were provided and reported according to the American College of Medical Genetics guidelines.
Immunohistochemistry
Routine immunohistochemical stains with synaptophysin (Biogenex, Fremont, CA, chromogranin (Leica) and S100 (Leica) were performed for diagnostic use in paraffinembedded tumor sections. For ATRX immunohistochemistry, a rabbit polyclonal anti-body (Sigma-Aldrich, St. Louis, MO) was used at a dilution of 1:100. After antigen retrieval, automated immunohistochemistry was performed in a Leica Bond Max instrument at CMH using standard protocols that included primary antibody, a secondary antibody, a polymer conjugate and a coloring reagent. Staining was evaluated by 2 observers and scoring was done following consensus of reviewed data. Only nuclear staining was considered for evaluation. The percentage of tumor cells with positive nuclear staining (heterogenous or homogenous and continuous pattern of stain) was calculated. Endothelial cells, stromal cells and infiltrating inflammatory cells served as internal positive controls.
RESULTS
Clinicopathologic Findings
A total of 96 patients with neuroblastic tumors (with the exclusion of ganglioneuroma) were retrieved from the archival records, and four of these patients fit the age criterion of being older than 10 years at the time of initial diagnosis. Ages ranged from 11 to 16 years with equal male/female ratio. Two patients presented with extra-adrenal abdominal masses and 2 with adrenal tumors (1 with bilateral adrenal masses). Tumor sizes ranged from 3 to 20 cm in maximum dimensions. All tumors were high risk and the clinical stage was assigned as 3 in 2 patients and 4 in the other 2. Distant metastasis was present in the bone marrow in both stage 4 patients. All 4 patients' tumors had a poorly differentiated, unfavorable histology (Figs. 1-3 
Cytogenetic Studies
Cytogenetic studies (FISH, chromosomes, CMA) were performed on each of the 4 patients. All cytogenetic test results are summarized in Table 2 . The array results are summarized in detail in Figure 4 .
Case Reports
Case 1
An 11-year-old female with the previous diagnosis of congenital qualitative platelet defect with thrombocytopenia presented with back pain and was found to have a left adrenal mass. Clinical symptoms at that time included poor appetite, headaches associated with vomiting and paresthesia of lower extremities when sitting > 20 minutes. There was no previous history of hypertension or virilization. Tests for urinary catecholamines revealed elevated homovanillic acid of 43.9 mg/gm creatinine (Cr) (normal range, 0 to 12.8) and vanillylmandelic acid of 68.7 mg/gm Cr (normal range, 0 to 8.2) which normalized after surgical resection. Serum chromogranin A was also elevated. The patient underwent full resection of the mass but continued to have hip and shoulder pain afterwards. The initial pathology interpretation from her resection was pheochromocytoma ( Fig. 1) . A bone scan done at her local hospital revealed avascular necrosis of right hip and shoulder, which supported the diagnosis of pheochromocytoma. However, her pain continued to worsen over the next few months so she underwent metastatic work up including 123 Imetaiodobenzylguanidine (MIBG) scan and bilateral bone marrow aspirates/biopsies, which demonstrated widespread bony metastasis. Disseminated pheochromocytoma was considered and chemotherapy with dacarbazine, cyclophosphamide and vincristine, which is the gold standard treatment for adults with pheochromocytoma, was recommended. She completed 1 cycle of chemotherapy with improvement in pain. However, the pathology of the bone marrow biopsy, which had been sent to several other institutions for additional pathologic opinions, revealed a morphology that was more consistent with NB ( Fig. 1) . The primary diagnosis was revised from pheochromocytoma to poorly differentiated NB. Because of the initial confusion and morphologic appearance resembling pheochromocytoma, additional immunohistochemical stains performed in other institutions revealed diffuse immunoreactivity for PHOX2b and normal staining pattern with succinate dehydrogenase B (data not shown). Tumor did not exhibit typical genetic changes associated with NB such as MYCN amplification nor chromosome 1 or 11 deletion. The patient completed 4 cycles of chemotherapy per ANBL0532, consisting of cyclophosphamide, topotecan, doxorubicin, etoposide, vincristine, and cisplatin with minimal radiologic response as evidenced by persistent widespread bony disease on MIBG. She was switched to ANBL1221 and underwent 4 cycles of irinotecan/temozolomide plus immunotherapy with dinutuximab after which she continued to have widespread stable metastatic disease. She was referred to another hospital for further experimental therapy, which failed. She ultimately died 21 months after initial presentation. Cytogenetic studies were performed on fresh tumor tissue from the diagnostic sample. Chromosome analysis of tumor tissue showed a normal karyotype. Concurrent CMA analysis revealed large deletions of 19p and 22q, the latter of which included NF2 and SMARCB1. Interphase FISH analysis for NF2 and SMARCB1 showed that the 22q deletion was present in the sample used for chromosome analysis. Interphase FISH analysis of bone marrow confirmed metastasis 
Case 2
A 13-year-old male patient presented with 2 weeks of abdominal pain associated with high fevers. A computed tomography (CT) scan revealed bilateral adrenal masses ( Fig. 2A) . A 123 I-MIBG scan and further work up showed avid uptake in left adrenal gland more than the right without evidence of bony lesions or other metastatic disease. The patient underwent left adrenalectomy and right adrenalsparing mass excision. The pathology of the left adrenal ALK-F1245V, MLL2-E550, and TERTpromoter 124C > T
ALK-F1174L
cnLOH indicates copy neutral loss of heterozygosity. mass was poorly differentiated NB; pathology of the right showed an intermixed ganglioneuroblastoma (Fig. 2) . Both tumors had a near-diploid DNA index of 1.1 by flow cytometry. As the tumors were completely resected and were cytogenetically favorable without MYCN amplification, the patient was carefully observed without further treatment per the recommendation of an outlying facility where parents sought second opinion. Four months later, the abdominal pain recurred and further work up revealed metastatic NB with a left renal fossa mass, para-aortic lymphadenopathy and bony metastases within the calvarium and fibular heads. The patient underwent 6 cycles of induction chemotherapy with topotecan, cytoxan, cisplatin, etoposide, doxorubicin, and vincristine and autologous transplant ×2 per ANBL0532 followed by radiation therapy to abdomen and bilateral femurs. Follow-up scans after radiation showed progression of disease to left retroperitoneum, bilateral femurs, left humerus and right parietal skull so the patient was started on salvage chemotherapy with temodar/irinotecan with dinutuximab for 2 cycles. Scans after the second cycle showed continued progression, with new left scapula and femur lesions. The femur lesion was biopsied and sent for molecular profiling which identified an ALK F1245V mutation. The patient was ineligible for phase I study of lorlatinib (NANT 2015-02) due to thrombocytopenia, so he was started on compassionate use of lorlatinib. He continued to have progressive NB and succumbed to his disease 23 months after initial diagnosis. Cytogenetic studies were performed on fresh tumor tissue from the diagnostic samples. Chromosome analysis was performed on right and left adrenal masses. Both samples were found to have the same derivative chromosome 19, which was the result of a translocation between chromosomes 2 and 19, that is, 46,XY,der(19)t(2;19)(p21; p13.2). This unbalanced rearrangement resulted in gain of distal 2p and loss of distal 19p. FISH analysis confirmed 2p gain with three copies each of MYCN and ALK. CMA studies helped to refine the breakpoints associated with the derivative 19 but did not identify additional copy number changes. Interphase FISH analysis of bone marrow samples was normal for MYCN and ALK copy numbers.
Case 3
A 16-year-old female presented with a 5-month history of right leg pain that had progressed to weakness, swelling and skin discoloration. Magnetic resonance imaging and PET scans revealed a large retroperitoneal mass which extended to the spine and displaced the right kidney and proximal colon. Biopsy of the mass revealed a poorly differentiated, unfavorable histology NB without MYCN amplification (Fig. 3) . She had spinal compression and neurovascular involvement but no evidence of metastatic disease. She underwent 4 cycles of induction chemotherapy per ANBL0532, consisting of topotecan, cyclophosphamide, doxorubicin, vincristine, etoposide, and cisplatin and had partial response to therapy. She was then referred to another institution for resection of the tumor where 95% resection was achieved. She developed a large hematoma postoperatively that required surgical intervention including ileostomy which was reversed 2 months later. She underwent proton beam radiation to the lumbosacral spine and pelvic tumor bed (21 Gy) with a lumbosacral boost (24 Gy). Because of an ALK F1174L mutation found on molecular testing at the outside facility, treatment with alectinib (ALK-inhibitor) was recommended over postoperative completion of chemotherapy, antibody, autotransplant and/ or retinoic acid, with which parents decided to move forward. After 8 months of alectinib therapy during which she had stable disease, she developed a new lesion in the soft tissues lateral to the lower pole of the right kidney and underwent resection with intraoperative radiation therapy. Pathology revealed 30% viable tumor. Alectinib therapy was discontinued she transferred care to a third facility where she is currently enrolled on NANT 2015-02 clinical trial receiving lorlatinib.
Interphase FISH on the diagnostic needle biopsy showed gain of one or 2 copies of the MYCN and AFF3 probes and 2 copies of the FOXO1 probes. There was no evidence of MYCN amplification. Metaphase chromosomes on this sample showed a near-triploid chromosome number; however, the chromosome morphology was poor, precluding complete analysis. Chromosome analysis of a second tumor biopsy sample (collected 3 d after the initial diagnosis) was normal. CMA of the second biopsy sample showed a complex series of copy number changes with gain of multiple whole chromosomes as well as segmental gains involving chromosomes 1, 11, 17, 19, and X. Copy neutral loss of heterozygosity (cnLOH) of whole chromosomes 2, 4, 9, 10, 11, and 22, and segmental cnLOH of 19p was also observed.
Case 4
A 12-year-old male presented with right shoulder pain, anemia, malaise, and fevers as well as migratory joint pain over the preceding weeks. CT scan and magnetic resonance imaging revealed a right pelvic mass measuring 6.4 cm (in maximum dimension) as well as a right shoulder effusion. The pathology from the bone marrow aspirate and biopsy showed stage 4 MYCN-amplified poorly differentiated NB with unfavorable histology (Fig. 3) . Subsequent bone scan and 123 I-MIBG revealed widespread metastatic disease in bilateral humeral heads, right sphenoid ridge, calvarium, left ilium, thoracolumbar spine and lower extremities. The patient underwent treatment per ANBL0532, regimen B randomized to tandem transplant arm. After completing 6 cycles of chemotherapy with cyclophosphamide, doxorubicin, vincristine, etoposide, cisplatin, and topotecan and after laparoscopic surgical resection of primary tumor, he underwent 2 autologous stem cell transplants. He then received radiation therapy with a boost to the primary tumor site. His postradiation therapy CT scan showed a small amount of residual presacral soft tissue thickening that was also positive by MIBG. Gross total resection of the residual tumor revealed MYCN nonamplified tumor. There was no evidence of metastatic disease at that time. He was about to start maintenance therapy with accutane when a repeat MIBG scan revealed a relapse of NB with 2 new foci in the left lower extremity as well as the left kidney. He was referred to another institution where he received 2 cycles of temozolomide and irinotecan, but unfortunately developed new disease progression. He was then started on palliative chemotherapy with cyclophosphamide and topotecan but did not qualify for any phase I trials due to transaminitis. He received 4 cycles of palliative chemotherapy before he developed bladder cystitis, renal failure, and respiratory insufficiency secondary to his disease. He died 18 months after initial diagnosis.
Chromosome analysis, initially performed on a bone marrow sample, showed a complex near-triploid karyotype consistent with the pathology diagnosis of metastatic NB.
FISH analysis of that sample showed cells with MYCN amplification and others with nonamplified MYCN gains. Subsequent FISH studies on the primary tumor showed MYCN gains, but no evidence of MYCN amplification. A chromosome study on the primary tumor sample did not identify any of the abnormalities seen on the initial study but did identify an apparently balanced clonal translocation between chromosomes 1 and 11. The significance of that translocation was uncertain. CMA performed on an FFPE sample from the primary tumor revealed a very complex series of copy number changes that were consistent with the original bone marrow FISH and chromosome studies. These copy number changes included whole chromosome gains, segmental gains involving 2p, 7q, 17, and X, and segmental losses involving 7, 9p, 15, and 19. The losses on 9p included bi-allelic deletions involving CDKN2A and PTPRD. Of note, the microarray did not show any indication of the MYCN amplification that was seen in the initial FISH study performed on the bone marrow sample.
DNA Sequencing Results
Gene variants of clinical significance detected by targeted sequencing included MAGI2 R564Q and RUNX1 R201Q in case 1; ALK F1245V, MLL2 E550 and TERT promoter 124C > T in case 2; and ALK F1174L in case 3. Several other gene variants of unknown clinical significance were also identified. For cases 2 and 3, DNA sequencing revealed a targetable mutation (ALK) that helped guide further treatment. Both patients were eventually treated with ALK-inhibitors (lorlatinib and/or alectinib) after failing conventional chemotherapy.
ATRX Immunohistochemistry
In normal tissue, ATRX displayed distinct and strong nuclear staining pattern, accompanied by a weaker cytoplasmic staining. Cases 1 to 3 showed diffuse retention of normal nuclear ATRX staining (90% to 100% positive staining), including the ganglioneuroblastoma tumor. Case 4 had a mosaic pattern in the primary tumor with focal loss of staining (40% to 50% positive staining). Staining was retained in the bone marrow metastasis (Figs. 3C, D) .
DISCUSSION
Neuroblastic tumors in patients older than 10 years of age are rare and comprise just 4.2% of patients in the CMH pathology archives (96 total). Although larger number of patients have already been published, this small case series emphasizes unusual clinicopathologic characteristics and discusses the role of DNA microarray analysis and next-generation sequencing in the management of these patients. Tumors presented with extensive visceral involvement, large size, lymph node involvement or distant metastasis, and high clinical stage. This type of presentation suggests a more indolent tumor course as compared with younger patients. Other unusual features included the presence of bilateral tumors and pheochromocytoma-like morphology in another case. Bilateral adrenal NB is rare and most of the reported cases occur in infants and young children and have favorable prognosis. 17, 18 Such presentation implies a multifocal disease occurring as part of a neurocristopathy syndrome. 19 We are aware of only very few cases where bilateral neuroblastic tumors were reported in adolescent children, as in case 2. 16, 20 In these cases, the possibility of a bilateral disease occurring as a metastasis from one tumor cannot be excluded.
Case 1 also illustrates the close relationship between NB and pheochromocytoma. Both tumors share the same origin from primitive neural crest cells, have similar biochemical secretory properties and express neuroendocrine markers. 21 The overall nested growth pattern in case 1 with the presence of S100-positive cells resembled the Zellbalen growth pattern of pheochromocytoma with its sustentacular cells. This morphologic mimicry resulted in the initial erroneous diagnosis of pheochromocytoma. However, on closer examination, the cytologic features of amphophilic granular cytoplasm, intermingling ganglion cells, and focal Schwannian stroma were more consistent with NB. The tumor morphology of the bone marrow specimens was typical of NB as well, and the final pathology interpretation was poorly differentiated NB, confirmed by consultation with known NB experts. Another case of NB with a similar pheochromocytoma-like morphology has been reported after chemotherapy. 22 One might argue that case 1 was an example of composite pheochromocytoma and the neuroblastic component resulted in bone marrow metastasis, as has rarely been reported in adults and children. [23] [24] [25] In composite cases, both tumors occur side by side and display a striking biphasic morphology with 2 distinct tumor types, unlike what is seen in case 1.
Our findings corroborate previously published reports where the majority of older NB patients presented with advanced clinical stage. 15, 26 Although presenting tumor locations were similar to younger children, older patients had more indolent tumor growth. 27 Patients were reported to have frequent late relapses and a prolonged, chemotherapy-resistant and ultimately fatal course. [26] [27] [28] [29] [30] [31] In patients older than 10 years, the overall survival at 5 and 10 years was 40% and 20%, respectively. 30 In a study of 13 adolescent patients with metastatic NB, the progression-free and overall survival was 18% and 27%, respectively. 26 This low survival is attributed to high clinical stage at presentation and is similar to that of younger children with stage 4 disease. 27 The treatment of such patients presents a dilemma due to the high incidence of resistance to conventional chemotherapy. Autologous hematopoietic cell transplant and immunotherapy may offer some advantage and improve survival. 28, 29 Resistance to chemotherapy and poor prognosis may be due to genetic mutations that are found with higher frequency in this age group, for example ATRX, ARID1A, and ARID1B. 30 Although not detected in our small series, loss-of-function mutations in the ATRX gene are found in 10% to 17% of NB cases in general and are more frequent in children older than 5 years, adolescents, and young adults with an incidence of up to 44%. They are associated with chemoresistance and late recurrence in long-term survivors. 31 ATRX immunohistochemistry has been successfully used to reflect gene mutation with near complete concordance. The lack of ATRX mutations and retention of protein expression in our case series indicate that other factors might have affected the chemoresistance and adverse clinical course. Our exome sequencing studies revealed ALK mutations as the most common genetic abnormality. ALK mutations are found in both familial and sporadic NB across all ages and in different clinical stages. Mutations in 3 positions (R1275, F1174, and F1245) account for about 85% of ALK mutations in NB. 32 Both F1174 and F1245 mutations are identified in 2 of our cases and are generally found in sporadic NB at high frequency. A recent study of 1596 diagnostic NB samples found that ALK mutations were associated with poor survival in high-risk and intermediate-risk disease, thus possibly explaining the adverse outcome in some of our cases. 33 Few published studies on older age NB have described the genetic characteristics associated with these tumors. 31, 34, 35 The genetic changes observed in our cases are consistent with the published older age NB patients tested by CMA (Table 3) . The overlapping findings with the previous studies include whole chromosome gains of 6, 7, 8, 13, 17, 18, and 20. The significance of this association is uncertain though, as 2 of our cases were near-triploid, with gains of most chromosomes. At least 2 of our cases also showed gains involving 2p (including MYCN) and 17q, both of which are segmental copy number alterations that are also reported in younger NB patients 31, 36 (Table 3) . We did not observe copy number losses as frequently as previously reported in older patients with NB, but did find deletions involving 19p in 3 of 4 cases. The only case in our cohort without a 19p deletion had overlapping 19p cn-LOH, suggesting that at one time there was a loss of one copy of 19p in this tumor, which was subsequently repaired. The involvement of 19p was the only genetic region shared among all 4 cases in our cohort (Fig. 4) . Deletions and cn-LOH involving 19p have previously been reported in both younger and older age NB patients, with one study reporting them in 5/ 17 adolescent/adult patients over 10 years of age, and another observing an enrichment of 19p LOH in NB patients over 5 years of age. 31, 35 This finding is of interest with regards to our cohort because the overall genomic profiles of our cases are very different with 2 cases showing complex near-triploid findings with numerous structural changes and the other 2 showing a relatively simple copy number profile, with no numerical chromosome alterations. This association, along with the fact that 19p aberrations have been observed in multiple studies, would suggest that the loss of 19p is significant to the development of NB in older patients. However, larger cohort studies would be needed to fully assess its specific clinical significance.
MYCN amplifications, which are observed in ∼20% to 25% of younger NB patients and ∼9% of NB patients over 10 years of age, were not observed in any of our tumor samples. 28, 37 However, case 4 did present with MYCN amplification in the metastatic bone marrow sample ( Table 2 ). The identification of MYCN amplification in a bone marrow sample, but not the primary tumor, has been reported in NB patients and is suggestive of genetic heterogeneity. 38 Interestingly, case 4 also had focal loss of ATRX expression in the primary tumor sample but retained ARTX expression in the bone marrow. The retained ATRX expression and presence of cells with MYCN amplification in the bone marrow sample would suggest that the metastasized cells in the bone marrow were derived in part from a minor clone of the tumor. Our inability to detect the MYCN amplification in the tumor by FISH or CMA is likely due to the MYCN amplified clone being present in a low percentage of cells at the time of study.
The presence of ALK mutations provided opportunities for targeted therapy with ALK inhibitors. Such treatment, however, was not quite successful in the 2 patients treated with lorlatinib and alectinib. Both drugs are second generation ALK inhibitors that have shown initial good results against the crizotinib-resistant tumors and good response in clinical trials of NB. 39, 40 MAGI2, RUNX1, and MLL2 variants have not been previously identified in NB. The runt related transcription factor (RUNX1) regulates the differentiation of hematopoietic stem cells and plays an important physiologic role in hematopoiesis. Mutations in RUNX1 have been implicated in various forms of hematopoietic diseases including familial cases with thrombocytopenia and qualitative platelet (25) abnormalities, thus explaining the platelet defect in case 1. 41, 42 RUNX1 mRNA was detected at high levels in NB cell lines and hence may play a role in NB cell proliferation. 43, 44 Thus, the RUNX1 variant in case 1 may have been the oncogenic driver for the patient's tumor. The membrane-associated guanylate kinase inverted 2 (MAGI2), also known as synaptic scaffolding molecule, is a central organizer of signaling proteins and plays a critical role in signal transduction by assembling and anchoring ligands. 45 MAGI2 is highly expressed in brain tissue and exists as a tumor suppressor. To our knowledge, this case represents the first case of NB found in association with MAGI2 and RUNX1 mutations.
In conclusion, NB in children older than 10 years of age may exhibit unusual clinicopathologic features with large tumors, bilateral adrenal disease, pheochromocytomalike features, complex DNA microarray results and rare genetic profiles. Such patients have high risk disease despite absence of the usual poor-prognostic factors. Although next-generation sequencing and targeted therapy may offer hope, patients may still have a dismal outcome.
